Table 3.
Comparison results of In-house ZIKV IgM ELISA, Euroimmun ZIKV IgM, and InBios ZIKV IgM ELISAs
| ELISA | Result* | Validation samples | Total | % Sensitivity (95% CI) | % Specificity (95% CI) | % Overall agreement (95% CI) | Kappa assessment (95% CI) | ||
|---|---|---|---|---|---|---|---|---|---|
| ZIKV | Other | NEG | |||||||
| In-house ZIKV-IgM | ZIKV | 59 | 8 | 0 | 67 | 59/67 | 72/80 | 131/147 | |
| Other (a) | 0 | 52 | 0 | 52 | 88.06% | 90.00% | 89.12% | 0.83 | |
| Negative | 8 | 0 | 20 | 28 | (77.9–94.1) | (81.3–95.1) | (83.0–93.3) | (0.74–0.91) excellence |
|
| Total | 67 | 60 | 20 | 147 | |||||
| Euroimmun ZIKV IgM | ZIKV | 9 | 1 | 0 | 10 | 9/67 | 79/80 | 88/147 | |
| Other (b) | 3 | 59 | 0 | 62 | 13.43% | 98.75% | 59.86% | 0.45 | |
| Negative | 55 | 0 | 20 | 75 | (7.0–23.8) | (92.6–100) | (51.8–67.4) | (0.34–0.56) fair | |
| Total | 67 | 60 | 20 | 147 | |||||
| InBios 2.0 ZIKV IgM | ZIKV | 63 | 7 | 0 | 70 | 63/67 | 73/80 | 130/147 | |
| Other (c) | 1 | 47 | 0 | 48 | 94.03% | 91.25% | 88.44% | 0.81 | |
| Negative | 3 | 6 | 20 | 29 | (85.2–98.1) | (82.8–96.0) | (82.2–92.7) | (0.73–0.90) excellence | |
| Total | 67 | 60 | 20 | 147 | |||||
IgM = immunoglobulin M; ZIKV = Zika virus.
*
Other includes a) 1°, 2° dengue virus, and Japanese encephalitis virus positive of validation; b) borderline for Euroimmun; and c) other flavivirus positive for InBios ZIKV IgM ELISAs.